Management of obesity
- PMID: 39325384
- DOI: 10.1093/ajhp/zxae273
Management of obesity
Abstract
Purpose: This review summarizes the comprehensive management of obesity with a focus on the pharmacology, efficacy, and safety of anti-obesity medications.
Summary: Obesity is a highly prevalent chronic disease with significant health risks, requiring a multifaceted approach to treatment. While most approved weight loss medications have modest effects, newer medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight. Optimal selection of therapy requires taking into consideration patient factors, such as comorbidities and goals, and medication-related factors, including weight loss efficacy, contraindications, and improvements in cardiovascular risk. As the availability of anti-obesity medications increases, multidisciplinary care teams will play an important role in selecting optimal strategies for long-term health benefits in individuals with obesity.
Conclusion: The expanding array of anti-obesity medications provides valuable treatment options alongside lifestyle interventions and surgical approaches for managing obesity and reducing weight-related health risks. As this therapeutic area continues to grow, selecting optimal agents and educating patients on administration, monitoring, and potential adverse effects will be critical for improving overall outcomes.
Keywords: endocrinology; new drug therapy; obesity; pharmacotherapy; weight loss.
© American Society of Health-System Pharmacists 2024. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Obesity Management in Adults: A Review.JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897. JAMA. 2023. PMID: 38015216 Free PMC article. Review.
-
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management.Pharmacotherapy. 2024 Sep;44(9):738-752. doi: 10.1002/phar.4607. Epub 2024 Sep 3. Pharmacotherapy. 2024. PMID: 39225417 Review.
-
Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States.J Manag Care Spec Pharm. 2025 May;31(5):441-450. doi: 10.18553/jmcp.2025.31.5.441. J Manag Care Spec Pharm. 2025. PMID: 40298310 Free PMC article.
-
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?Curr Obes Rep. 2021 Mar;10(1):14-30. doi: 10.1007/s13679-020-00422-w. Epub 2021 Jan 6. Curr Obes Rep. 2021. PMID: 33410104 Free PMC article. Review.
-
Drugs for Treating Obesity.Handb Exp Pharmacol. 2022;274:387-414. doi: 10.1007/164_2021_560. Handb Exp Pharmacol. 2022. PMID: 34783910
Cited by
-
Application of Polyglycolic Acid/Poly (Lactic-co-glycolic Acid) in Thread Embedding Acupuncture for Obesity: New Strategies and Challenges.Diabetes Metab Syndr Obes. 2025 Jul 5;18:2175-2189. doi: 10.2147/DMSO.S525783. eCollection 2025. Diabetes Metab Syndr Obes. 2025. PMID: 40636750 Free PMC article. Review.
-
New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes.Medicina (Kaunas). 2025 Apr 3;61(4):664. doi: 10.3390/medicina61040664. Medicina (Kaunas). 2025. PMID: 40282955 Free PMC article. Review.
-
Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.Cureus. 2025 Jun 15;17(6):e86080. doi: 10.7759/cureus.86080. eCollection 2025 Jun. Cureus. 2025. PMID: 40666599 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials